INTERNAL USE FOR TRAINING PURPOSES INTERNAL USE FOR TRAINING PURPOSES. STRICTLY NOT TO BE CIRCULATED TO CUSTOMERS. 瑞士銀行現況 2008.12.29

瑞士銀行現況 財務穩定性/實力：瑞銀是世界上資本最健全的金融服務公司之一 2008年10月16日，瑞銀集團與瑞士國家銀行達成了協定：將把瑞銀資產負債表上價值600億美元的不良資產轉移到由瑞士國家銀行管理的基金公司。瑞銀預期將在2008年第4季到2009年第1季間轉移資產 通過與瑞士國家銀行的交易，瑞銀控制住了不良資產造成的未來的潛在損失，減少了風險資產的數量，從本質上降低了風險，並不再受到此類資產融資的風險。該結果使瑞銀成為了擁有行業內狀況最好的資產負債表的公司之一 瑞銀集團的BIS（國際銀行結算）一級資本適足率為10.8%（截至9月30日），行業內最好之一。相對於行業內，瑞銀維持住了很高的信用評級：Aa2（穆迪），A+（標準普爾），A+（惠譽） 客戶受益: 安全與可靠的交易對象 , 能夠提供具有競爭力的利率, 穩定，長期的夥伴 傑出的收購與發展：瑞銀已吸引了一批世界級的資深精英團隊 在2008年，公司進行了重要的人員增加，特別是在執行管理層。包括全球固定收益業務主管（Jeffrey Mayer 和 Carsten Kengeter）和最高風險控制主管（Tom Daula） 截至年底，瑞銀投資銀行將擁有17,000名專家，在34個國家內運作，致力服務于我們客戶的需求 客戶受益: 強大的精英團隊幫助客戶取得成功

瑞士銀行現況 市場和信用風險管理：經過領先市場的果斷行動，瑞銀風險已大幅降低 信用風險似乎已經深入到受總體經濟影響的相關商業領域，特別是信用卡和汽車貸款。而瑞銀不含有全球性的消費金融業務 作爲與瑞士國家銀行交易的一部分，瑞銀剩餘的次級債相關部位，ALT-A住房抵押貸款和商業房地產將會從資產負債表中除去。通過這項轉移，瑞銀集團所有資產的風險曝露部位淨值為7億美元 客戶受益: 安全與可靠的交易對象 ; 我們有能力進一步提高頂級客戶服務 商業成就：通過全球平台，瑞銀在每一個主要的金融市場都提供了專家服務，特別是對於新興市場 瑞銀集團的眾多業務深受好評，多次獲得獎項和排名上榜，多次獲得所在地區的榮譽，如“Euromoney-2008亞洲最優秀投資銀行”，”IFR-Best Global Equity House”，”The Banker – IPO House of the Year” 等 客戶受益: 自信的決策力， 最好的執行力以及為全世界主要市場提供高品質建議 管理方式： 對管理方式進行了修改，並結合改進後的風險管理控制來增加靈活性，敏捷性，和效率 瑞銀將通過對業務的分隔來增強自動化，操作力和責任性，以此來提高決策速度。新的管理方式和四名新董事會員將帶來更好的監控和風險管理 客戶受益: 靈活性，敏捷性，和效率的提高；對已有業務不造成任何影響；全球提供統一的產品與服務

瑞銀與瑞士央行進行交易後風險大幅降低 UBS於2008/11/27召開特別股東大會，其中董事會主席Peter Kurer特別針對UBS現狀與未來前景發表談話: 我們已經與瑞士國家銀行簽訂了一項協議，允許瑞銀將上限600億美元的不良資產轉移到新成立的基金實體。 這一轉移將有助於降低風險資產及改善我們的資產負債表。 因此我們對於已轉移的不良資產，未來不會再有進一步的資產減記，這將大幅減少股東和客戶的不確定性。 瑞銀有權在全數清還貸款後購回股權，購回價為10億美元加上其資產淨值中超出10億美元的數額的其中一半。 MCN將支付12.5%的票面息，直至被轉換為瑞銀註冊股份。MCN必須於發行後不遲於30個月轉換。 在貸款批出時，瑞士央行將以1美元的名義價格購入瑞銀的股權，從而取得該實體的控制權及所有權。 瑞銀將以強制性可轉換票據（MCN）的形式，籌集60億瑞郎的新資金。 瑞銀將向基金提供最高達60億美元的股本 瑞士央行將向基金提供最高540億美元以基金資產作為抵押的貸款。 瑞士央行假設瑞銀控制權維持不變而向瑞銀提供此無追索權貸款，並將按LIBOR+2.5%釐定利率。此項貸款於8年後到期償還，但還款期可延長至10年或12年。 瑞銀與瑞士央行達成的協議，瑞銀將把最高達600億美元的資產，轉移至新設的基金實體。

Disclaimer Global Disclaimer This material has been prepared by UBS AG, or an affiliate thereof ("UBS"). In certain countries UBS AG is referred to as UBS SA. This material is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any recipient. It is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the materials. It should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this material are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. UBS is under no obligation to update or keep current the information contained herein. UBS, its directors, officers and employees' or clients may have or have had interests or long or short positions in the securities or other financial instruments referred to herein and may at any time make purchases and/or sales in them as principal or agent. UBS may act or have acted as market-maker in the securities or other financial instruments discussed in this material. Furthermore, UBS may have or have had a relationship with or may provide or has provided investment banking, capital markets and/or other financial services to the relevant companies. Neither UBS nor any of its affiliates, nor any of UBS' or any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this material. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this presentation. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisers to the extent you deem necessary to make your own investment, hedging and trading decisions. Any transaction between you and UBS will be subject to the detailed provisions of the term sheet, confirmation or electronic matching systems relating to that transaction. Clients wishing to effect transactions should contact their local sales representative. Additional information will be made available upon request. For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC and/or UBS Capital Markets LP) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this material. United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is communicated by UBS Limited, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients (as detailed in the FSA Rules) and is only available to such persons. The information contained herein does not apply to, and should not be relied upon by retail clients. UBS Limited is regulated by the FSA. France: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the Autorité des Marchés Financiers (AMF).  Where an analyst of UBS Securities France S.A.  has contributed  to this material, the material is also deemed to have been prepared by UBS Securities France S.A. Germany: Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt fur Finanzdienstleistungsaufsicht (BaFin). Spain: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). Turkey: Prepared by UBS Menkul Degerler AS on behalf of and distributed by UBS Limited. Russia: Prepared and distributed by the Moscow Representative Office of UBS Cyprus Moscow Limited. Switzerland: These materials are distributed in Switzerland by UBS AG to persons who are institutional investors only. Italy: Prepared by UBS Limited and distributed by UBS Limited and UBS Italia Sim S.p.A.. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB).   Where an analyst of UBS Italia Sim S.p.A.  has  contributed  to this material, the material is also deemed to have been prepared by UBS Italia Sim S.p.A.. South Africa: UBS South Africa (Pty) Limited (Registration No. 1995/011140/07) is a member of the JSE Limited, the South African Futures Exchange and the Bond Exchange of South Africa. UBS South Africa (Pty) Limited is an authorised Financial Services Provider. United States: These materials are distributed by UBS Securities LLC or UBS Financial Services Inc., subsidiaries of UBS AG, or solely to US institutional investors by UBS AG or a subsidiary or affiliate thereof that is not registered as a US broker-dealer (a "non-US affiliate"). Transactions resulting from materials distributed by a non-US affiliate must be effected through UBS Securities LLC or UBS Financial Services Inc. Canada: These materials are being distributed in Canada by UBS Securities Canada Inc., a subsidiary of UBS AG and a member of the principal Canadian stock exchanges & CIPF. Hong Kong: The materials relating to equities and other securities business, and related research, are being distributed in Hong Kong by UBS Securities Asia Limited. The material relating to corporate finance, foreign exchange, fixed income products and other banking business, and related research, are being distributed in Hong Kong by UBS AG, Hong Kong Branch. Singapore: Distributed by UBS Securities Pte. Ltd or UBS AG, Singapore Branch. Japan: The materials relating to equities, fixed income products, corporate finance and other securities business, and related research, are distributed in Japan by UBS Securities Japan Ltd. The materials relating to foreign exchange and other banking business, and related research, are distributed in Japan by UBS AG, Tokyo Branch. Australia: These materials are distributed in Australia by UBS AG (Holder of Australian Financial Services Licence No. 231087) and UBS Securities Australia Ltd (Holder of Australian Financial services Licence No. 231098). New Zealand: These materials are distributed in New Zealand by UBS New Zealand Ltd. ◎ 2007 UBS. All rights reserved. UBS specifically prohibits the redistribution of this material and accepts no liability whatsoever for the actions of third parties in this respect.